KR20200116110A - 5-히드록시트립토판 생체이용률을 높이는 조성물 및 방법 - Google Patents

5-히드록시트립토판 생체이용률을 높이는 조성물 및 방법 Download PDF

Info

Publication number
KR20200116110A
KR20200116110A KR1020207024221A KR20207024221A KR20200116110A KR 20200116110 A KR20200116110 A KR 20200116110A KR 1020207024221 A KR1020207024221 A KR 1020207024221A KR 20207024221 A KR20207024221 A KR 20207024221A KR 20200116110 A KR20200116110 A KR 20200116110A
Authority
KR
South Korea
Prior art keywords
htp
carbidopa
dose
low
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207024221A
Other languages
English (en)
Korean (ko)
Inventor
제이콥 피.알. 제이콥센
마크 지. 카론
Original Assignee
듀크 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 듀크 유니버시티 filed Critical 듀크 유니버시티
Priority to KR1020257004583A priority Critical patent/KR20250025043A/ko
Publication of KR20200116110A publication Critical patent/KR20200116110A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207024221A 2018-01-29 2019-01-28 5-히드록시트립토판 생체이용률을 높이는 조성물 및 방법 Ceased KR20200116110A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257004583A KR20250025043A (ko) 2018-01-29 2019-01-28 5-히드록시트립토판 생체이용률을 높이는 조성물 및 방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862623073P 2018-01-29 2018-01-29
US62/623,073 2018-01-29
US201862743816P 2018-10-10 2018-10-10
US62/743,816 2018-10-10
PCT/US2019/015391 WO2019148087A1 (en) 2018-01-29 2019-01-28 Compositions and methods of enhancing 5-hydroxytryptophan bioavailability

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257004583A Division KR20250025043A (ko) 2018-01-29 2019-01-28 5-히드록시트립토판 생체이용률을 높이는 조성물 및 방법

Publications (1)

Publication Number Publication Date
KR20200116110A true KR20200116110A (ko) 2020-10-08

Family

ID=67395723

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207024221A Ceased KR20200116110A (ko) 2018-01-29 2019-01-28 5-히드록시트립토판 생체이용률을 높이는 조성물 및 방법
KR1020257004583A Pending KR20250025043A (ko) 2018-01-29 2019-01-28 5-히드록시트립토판 생체이용률을 높이는 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257004583A Pending KR20250025043A (ko) 2018-01-29 2019-01-28 5-히드록시트립토판 생체이용률을 높이는 조성물 및 방법

Country Status (14)

Country Link
US (1) US11337963B2 (https=)
EP (1) EP3746058B1 (https=)
JP (2) JP7758320B2 (https=)
KR (2) KR20200116110A (https=)
CN (1) CN111902137A (https=)
AU (1) AU2019211458B2 (https=)
BR (1) BR112020015068A2 (https=)
ES (1) ES2948788T3 (https=)
IL (1) IL276059B2 (https=)
MX (1) MX2020007760A (https=)
MY (1) MY209656A (https=)
RU (1) RU2020125170A (https=)
SG (1) SG11202007178VA (https=)
WO (1) WO2019148087A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12409163B2 (en) * 2021-07-30 2025-09-09 Evecxia Therapeutics, Inc. Method of enhancing 5-hydroxytryptophan (5-HTP) exposure
WO2023009841A1 (en) * 2021-07-30 2023-02-02 Evecxia Therapeutics, Inc. 5-hydroxytryptophan gastroretentive dosage forms
US11779567B2 (en) 2021-10-14 2023-10-10 Evecxia Therapeutics, Inc. Method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes
DE102022103658A1 (de) * 2022-02-16 2023-08-17 Joachim Kamprad Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer
WO2024148354A1 (en) 2023-01-06 2024-07-11 Evecxia Therapeutics, Inc. A method of enhancing 5-hydroxytryptophan (5-htp) exposure
CN119074695A (zh) * 2024-08-29 2024-12-06 江南大学 一种可提高脑内5-ht水平的口服缓释制剂及其在改善失眠中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4658038A (en) 1982-10-07 1987-04-14 Research Foundation For Mental Hygiene, Inc. N-acylated 5-hydroxytryptophan amide derivatives
FR2654931B1 (fr) * 1989-11-24 1993-08-27 Trouillas Paul Compositions pharmaceutiques possedant une activite sur l'ataxie et les troubles de l'equilibre, cerebelleux ou autres, de toutes origines, comprenant l'association de l-5-hydroxytryptophane et de carbidopa.
CA2290624C (en) 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US6207699B1 (en) 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20060013875A1 (en) 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
EP1746985A4 (en) * 2004-05-21 2010-08-11 Univ Duke METHOD FOR INCREASING THE EFFECT OF SEROTONINE RECOVERY INHIBITORS
US20070213370A1 (en) 2005-11-18 2007-09-13 H. Lundbeck A/S 5-HTP Combination Therapy
US8969400B2 (en) 2007-10-01 2015-03-03 Duke University Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound
JP2012500221A (ja) 2008-08-15 2012-01-05 ディポメド，インコーポレイティド Ｃｎｓ障害の処理及び予防のための胃保持性医薬組成物
RU2012133467A (ru) * 2010-02-05 2014-02-10 Фосфейдженикс Лимитед Композиция носителя
EP2629615B1 (en) * 2010-10-22 2018-10-10 Duke University Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
CN103554005A (zh) 2013-11-22 2014-02-05 长沙理工大学 一种左旋5-羟基色氨酸的简便合成新方法

Also Published As

Publication number Publication date
BR112020015068A2 (pt) 2021-01-05
IL276059B2 (en) 2024-08-01
EP3746058B1 (en) 2023-06-07
EP3746058A4 (en) 2021-12-22
JP7758320B2 (ja) 2025-10-22
AU2019211458B2 (en) 2024-08-29
MX2020007760A (es) 2020-10-28
CN111902137A (zh) 2020-11-06
AU2019211458A1 (en) 2020-08-06
EP3746058C0 (en) 2023-06-07
JP2023153871A (ja) 2023-10-18
ES2948788T3 (es) 2023-09-19
KR20250025043A (ko) 2025-02-20
US11337963B2 (en) 2022-05-24
RU2020125170A (ru) 2022-02-28
WO2019148087A1 (en) 2019-08-01
EP3746058A1 (en) 2020-12-09
JP2021511365A (ja) 2021-05-06
IL276059A (en) 2020-08-31
US20210346345A1 (en) 2021-11-11
IL276059B1 (en) 2024-04-01
CA3089068A1 (en) 2019-08-01
MY209656A (en) 2025-07-29
SG11202007178VA (en) 2020-08-28

Similar Documents

Publication Publication Date Title
EP3746058B1 (en) Compositions and methods of enhancing 5-hydroxytryptophan bioavailability
Kadriu et al. Glutamatergic neurotransmission: pathway to developing novel rapid-acting antidepressant treatments
Harkin et al. Nitric oxide synthase inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test
Zurowski et al. Exogenous melatonin abolishes mechanical allodynia but not thermal hyperalgesia in neuropathic pain. The role of the opioid system and benzodiazepine-gabaergic mechanism
US8969417B2 (en) Pharmaceutical compositions for treatment of Parkinsons disease
US8969400B2 (en) Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound
Rivara et al. Therapeutic uses of melatonin and melatonin derivatives: a patent review (2012–2014)
JP2020520968A (ja) Ｎｍｄａｒアンタゴニスト−応答性精神神経障害のための併用療法
SK14612003A3 (sk) Použitie enantiomérne čistého escitalopramu a farmaceutický prostriedok s obsahom escitalopramu
JP5842058B2 (ja) 自閉症の治療における使用のためのクレンブテロール
EP2145620A2 (en) Gaboxadol for treating depression and other affective disorders
KR20060032598A (ko) 세로토닌 재흡수 억제제 및 아고멜라틴의 조합
Deng et al. Exploring the interaction between the gut microbiota and cyclic adenosine monophosphate-protein kinase A signaling pathway: a potential therapeutic approach for neurodegenerative diseases
Celikyurt et al. Serotonin noradrenaline reuptake inhibitors (SNRIs)
CA3089068C (en) Low-dose carbidopa for enhancing 5-hydroxytryptophan bioavailability
EP3060214A2 (en) Cns stimulant and opioid receptor antagonist combination as a non- addictive, non-aversive and synergistic anti-obesity treatment
KR20220106960A (ko) 경구 제약 즉시 방출 조성물 및 체중 감량을 위한 치료 방법
EP4626452A1 (en) Novel association of active ingredients, pharmaceutical and/or nutraceutical compositions containing it and their use in the prevention and repair of damage to the central and peripheral nervous system
Capuano et al. Flupirtine antinociception in the rat orofacial formalin test: an analysis of combination therapies with morphine and tramadol
WO2008035177A2 (en) Combination of mt1 and mt2 melatonin receptor agonists and a norepinephrine/dopamine reuptake inhibitor
Ding et al. Ketamine as a rapid-acting antidepressant: A scoping review of mechanisms and efficacy in treatment-resistant depression
ZA200509356B (en) Gaboxadol for treating depression and other affective disorders
EA011926B1 (ru) Пероральный антидепрессивный состав, включающий ацетилсалициловую кислоту для ускорения начала действия
Henter et al. Novel therapeutic targets for bipolar disorder
Desai et al. MEMANTINE FOR ALZHEIMER'S DISEASE

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200821

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220106

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231120

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240715

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

AMND Amendment
PX0901 Re-examination

Patent event code: PX09012R01I

Patent event date: 20241015

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20241111

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20241111

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250212